Hemab Therapeutics Holdings, Inc. COAG 深 沪
等待开盘 08-25 09:30:00 美东时间
47.30
-1.860
-3.78%
华盛通- 最 高50.149
- 今 开49.10
- 成交量 20.72万股
- 最 低 46.585
- 昨 收 49.16
- 总市值 22.09亿
- 52周最高 55.42
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 23.0001
- 委 比 52.38%
- 总股本 4671.21万
- 历史最高 55.42
- 量 比 0.78
- 振 幅 7.25%
- 历史最低 23.0001
- 每 手 1
- 风险率 10.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"
Celebrating 20 Years of Honoring the Digital Breakthroughs, Pioneering Startups, and Ecosystems Driving the Future of Healthcare NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Galien Foundation...
08-13 21:00
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60
HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.
08-12 00:14
Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.52) by 53.85 percent. This is a 93.8 percent increase over losses of $(12.91) per share from the same period last year.
08-11 19:07
美股周涨跌榜 | 迷幻药企业ATAI劲升近40%！获礼来38亿美元收购；PayPal升22%
迷幻药企业ATAI劲升近40%！获礼来38亿美元收购；PayPal升22%，拟获Stripe斥资530亿美元收购；AI交易集体熄火，费城半导体指数跌入熊市，闪迪重挫29%>>
07-18 10:30
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Hemab Advances Bleeding Disorder Pipeline
Hemab Therapeutics Inc. (NASDAQ:COAG) on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease (VWD) and introduced HMB-003, a new program targeting heavy menstrual bleeding, at the International Society on Thrombosis and Hemostasis (ISTH) 2026 Congress. The com...
07-14 01:47
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52
HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $40 to $52.
07-13 18:05
美股周涨跌榜 | 制药企业CRNX周内劲升97%，获福泰制药百亿美元高溢价收购；金山云周涨近2成
制药企业CRNX周内劲升97%，获福泰制药百亿美元高溢价收购；PENG周涨27%，Q3财季业绩超预期并上调全年指引；金山云周涨近2成，大摩称其盈利能力持续提升>>
07-11 11:01
